Table II.

HHV-8 shedding rates and quantities detected in oropharyngeal swabs collected among participants completing both study arms, for A. by study arms, and B. by HAART use.

A)
	Total (n=58)	Placebo (n=58)	Valacyclovir (n=42)	Famciclovir (n=16)
Overall frequency of HHV-8 detection, oropharyngeal swabs with HHV-8 detected/all swabs (%)	1128/6036 (19)	618/2992 (21)	323/2221 (15)	187/823 (23)
Person-level frequency (%)of HHV-8 detection, median (IQR)	2 (0–23)	2 (0 – 34)	2 (0 – 10)	0 (0 – 51)
HHV-8 DNA quantity* (log10 copies/mL), median (IQR)	4.68 (3.67–5.72)	4.44 (3.61–5.31)	5.26 (3.80–6.3)	4.68 (3.80–5.56)

B)
	HAART (n= 17)	No HAART (n= 41)
Overall frequency of HHV-8 detection, oroparyngeal swabs with HHV-8 detected/all swabs (%)	93/1761 (5)	1034/4074 (25)
Person-level frequency (%) of HHV-8 detection, median (IQR)	0 (0, 2)	4 (0, 38)
HHV-8 DNA quantity* (log10 copies/mL), median (IQR)	4.62 (3.42–5.53)	4.69 (3.67–5.73)

^*On days with detectable HHV-8